EBS - Emergent BioSolutions: Punished For Answering The Call To Immediate Action
- Emergent BioSolutions has had a rough go over the past couple of months resulting from a cross-contamination mishap at their Baltimore facility.
- Due to the cross contamination, the company had to toss millions of Johnson & Johnson vaccines. Consequently, the FDA put a halt on vaccine production at that facility.
- Following the news, EBS share price has been cut in half and crushed to new 52-week lows. I believe there is an opportunity for a quick reversal play.
- The company's latest quarter earnings and updated guidance point to record revenues in 2021. The market will find it hard to ignore double-digit growth over the rest of 2021.
For further details see:
Emergent BioSolutions: Punished For Answering The Call To Immediate Action